Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease

Table 4 Hepatoxicity profile of the commonly used drugs to treat coronavirus disease 2019 infection

Medication	Hepatotoxicity pattern
Dexamethasone	None reported at the dose given for COVID
Protease inhibitors (e.g., lopinavir, ritonavir)	Mostly hepatitis pattern with ALT raise up to 6 times the normal, but rarely cholestatic pattern reported[43]
Nucleoside analogue: Remdesivir	Hepatitis pattern with mild to moderate ALT raise (up to 6 times the normal)[77]
Monoclonal antibodies to IL-6: Tocilizumab	Rarely can cause acute severe hepatitis in patients on concomitant or previous hepatotoxic drug usage[83]

ALT: Alanine transaminase; COVID: Coronavirus disease; IL-6: Interleukin-6.